GlobeNewswire: Admera Health, LLC Contains the last 10 of 24 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:46:01ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/05/26/2038701/0/en/Hygea-and-Admera-Health-a-CLIA-Certified-CAP-Accredited-Laboratory-Announce-Formal-Partnership.html?f=22&fvtc=4&fvtv=28441Hygea and Admera Health, a CLIA Certified/CAP Accredited Laboratory, Announce Formal Partnership2020-05-26T13:13:00Z<![CDATA[SAN FRANCISCO and SOUTH PLAINFIELD, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Hygea Precision Medicine (Hygea), a company focused on developing a precision medicine software system for healthcare providers and patients to effectively manage genomic testing, and Admera Health, a premier precision medicine company and genetics laboratory, are pleased to announce a formal, agreed partnership.]]>https://www.globenewswire.com/news-release/2019/12/10/1958780/0/en/Admera-Health-Announces-Appointment-of-Omar-Karame-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=28441Admera Health Announces Appointment of Omar Karame as Chief Financial Officer2019-12-10T16:45:38Z<![CDATA[SOUTH PLAINFIELD, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Admera Health, a molecular diagnostics company, welcomes Omar Karame as Chief Financial Officer to the company. Mr. Karame brings to Admera Health more than 20 years of finance and capital markets experience. Prior to joining Admera Health, Mr. Karame was CFO of an energy technology company in addition to heading M&A activities for several different businesses, including a Fortune 500, NYSE listed contractor, an NYSE listed healthcare company and a $1.4 billion industrial holding company. In addition, Mr. Karame spent several years in private equity, venture capital, and investment banking working on notable healthcare transactions such as the IPO of DaVita (formerly, Total Renal Care Holdings), the merger of National Medical Enterprises and American Medical Holdings in the creation of Tenet Healthcare, and the divestiture and spin-offs of Priority Hospital Groups and Transitional Hospitals Corporation from NYSE listed Community Psychiatric Centers. Mr. Karame received his MBA from the Wharton Business School and Bachelor of Arts from Dartmouth College.]]>https://www.globenewswire.com/news-release/2019/08/20/1904238/0/en/Inc-Magazine-Unveils-Its-Annual-List-of-America-s-Fastest-Growing-Private-Companies-the-Inc-5000.html?f=22&fvtc=4&fvtv=28441Inc. Magazine Unveils Its Annual List of America’s Fastest-Growing Private Companies—the Inc. 50002019-08-20T13:13:00Z<![CDATA[Admera Health Ranks No. 511 on the 2019 Inc. 5000 With Three-Year Revenue Growth of 855 Percent Admera Health Ranks No. 511 on the 2019 Inc. 5000 With Three-Year Revenue Growth of 855 Percent]]>https://www.globenewswire.com/news-release/2019/04/02/1795384/0/en/Massive-Bio-to-Present-SYNERGY-AI-Trial-in-Progress-Poster-Presentation-at-Upcoming-AACR-2019-using-its-AI-Clinical-Trial-Matching-Technology-and-Announces-Strategic-Partnership-in.html?f=22&fvtc=4&fvtv=28441Massive Bio to Present SYNERGY-AI Trial-in-Progress Poster Presentation at Upcoming AACR 2019 using its AI Clinical Trial Matching Technology, and Announces Strategic Partnership in Precision Oncology with US-Based Admera Health2019-04-02T14:02:45Z<![CDATA[NEW YORK, April 02, 2019 (GLOBE NEWSWIRE) -- Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at community-based oncology practices, announced today that its Trials-in-Progress poster titled “SYNERGY-AI: Artificial intelligence based precision oncology clinical trial matching and registry” will be presented by Dr. Selin Kurnaz, a lead investigator, at the American Association of Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA, USA, during the Phase I-III Trials in Progress session on April 2nd, 2019.]]>https://www.globenewswire.com/news-release/2019/02/26/1742561/0/en/Chinese-Based-MedCDx-and-US-Based-Admera-Health-Enter-Into-Strategic-Partnership-to-Co-Develop-Companion-Diagnostics.html?f=22&fvtc=4&fvtv=28441Chinese-Based MedCDx and US-Based Admera Health Enter Into Strategic Partnership to Co-Develop Companion Diagnostics2019-02-26T14:21:00Z<![CDATA[SOUTH PLAINFIELD, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Today, MedCDx and Admera Health announced a non-exclusive collaborative agreement. Under the terms of the agreement, MedCDx (formerly Qiagen Suzhou Translational Medicine) and Admera Health will gain access to each other’s existing portfolios and co-develop new technologies, specifically companion diagnostics.]]>https://www.globenewswire.com/news-release/2018/12/11/1665239/0/en/Admera-Health-Genetic-Tests-are-Now-In-Network-with-CareFirst-BlueCross-BlueShield-Maryland-Washington-D-C-and-Northern-Virginia.html?f=22&fvtc=4&fvtv=28441Admera Health Genetic Tests are Now In-Network with CareFirst BlueCross BlueShield, Maryland, Washington D.C, and Northern Virginia2018-12-11T14:13:00Z<![CDATA[SOUTH PLAINFIELD, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Admera Health (www.admerahealth.com), an advanced molecular diagnostics company, announced today that its genetic testing services are now available as in-network benefits under CareFirst Blue Cross Blue Shield. With over 3.2 million members, CareFirst offers the widest coverage and the largest network for medical, dental and vision insurance in Maryland, Washington D.C., and Northern Virginia. Their expansive network provides members with access to more than 1 million physicians, provider facilities, hospitals, and care centers. CareFirst has been providing health insurance to the region for over 75 years and is nationally recognized for its customer service for their members.]]>https://www.globenewswire.com/news-release/2018/12/04/1661795/0/en/Admera-Health-Adds-Clinical-Genomics-Expert-Dr-Ruben-Bonilla-Guerrero-to-Management-Team.html?f=22&fvtc=4&fvtv=28441Admera Health Adds Clinical Genomics Expert, Dr. Ruben Bonilla-Guerrero, to Management Team2018-12-04T14:13:00Z<![CDATA[SOUTH PLAINFIELD, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Admera Health, a molecular diagnostic company, welcomes Dr. Ruben Bonilla-Guerrero as Medical Director to the company. Ruben Bonilla-Guerrero obtained his M.D. from the Universidad Veracruzana in Mexico followed by 14 years working experience at Mayo Clinic in Minnesota, including fellowships in Experimental Pathology, Clinical Pharmacology, and Clinical Biochemical Genetics. Prior to joining Admera Health, Dr. Bonilla-Guerrero held the titles of Medical Director, Medical Affairs, Genetics, and Associate Medical Director, Genetics at Quest Diagnostics, Inc. Quest Diagnostics is a national reference laboratory focused on diagnostic testing, laboratory information, and services. At Quest Diagnostics, Dr. Bonilla-Guerrero was credited for his outstanding analytical skills as well as an invaluable set of clinical insights which he applied to clinical laboratory medicine, inborn errors of metabolism, and pharmacogenetics genotyping.]]>https://www.globenewswire.com/news-release/2018/10/23/1625547/0/en/Admera-Health-Expands-Liquid-Biopsy-Offering-to-Include-Detection-of-Copy-Number-Variation-and-Microsatellite-Instability.html?f=22&fvtc=4&fvtv=28441Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability2018-10-23T13:13:00Z<![CDATA[SOUTH PLAINFIELD, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based LiquidGx™ test for solid tumor-targeted therapy selection from a blood sample. This extended version increases the utility of the assay by raising the number of genes to 17 and including detection of copy number variation and microsatellite instability.]]>https://www.globenewswire.com/news-release/2018/09/25/1575824/0/en/Admera-Health-Teams-with-Allure-Specialty-Pharmacy-to-Offer-PharmD-Fellowship-Program.html?f=22&fvtc=4&fvtv=28441Admera Health Teams with Allure Specialty Pharmacy to Offer PharmD Fellowship Program2018-09-25T13:14:52Z<![CDATA[SOUTH PLAINFIELD, N,J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Today, Admera Health, a molecular diagnostics company, in conjunction with Allure Specialty Pharmacy announced the launch of a Post-Doctoral PharmD Fellowship Program focused on pharmacogenomics. The Admera Health-Allure Specialty Pharmacy Program is a multi-site fellowship program that includes two longitudinal experiences integrated over 24 months and is designed to offer an in-depth experience in pharmacogenomics from the standpoint of medical education as well as clinical integration at an ambulatory care pharmacy.]]>https://www.globenewswire.com/news-release/2018/06/26/1529723/0/en/Admera-Health-Announces-Availability-of-Psychiatric-Specific-Report-PGxPsych-for-its-PGxOne-Plus-Pharmacogenomics-Test.html?f=22&fvtc=4&fvtv=28441Admera Health Announces Availability of Psychiatric Specific Report, PGxPsych™, for its PGxOne™ Plus Pharmacogenomics Test2018-06-26T13:13:00Z<![CDATA[SOUTH PLAINFIELD, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- Today, Admera Health (www.admerahealth.com), announced the availability of a psychiatric specific report for its PGxOne™ Plus pharmacogenomics test. PGxOne™ Plus is a laboratory developed test that includes over 50 genes, over 200 DNA variants (affecting drug metabolism, transportation, and activation), and provides recommendations for over 300 drugs via Next Generation Sequencing. This new report format, named PGxPysch™, provides easier access to favorable drug recommendations for therapeutics routinely used to treat symptoms associated with mental health disease based on a patient’s DNA. Also included, is an analysis of relevant mental health drugs that are metabolized by multiple enzymatic pathways.]]>